| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.07 | 0.04 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.096 | 0.04 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.37 | 0.04 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | 0.33 | 0.04 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.061 | 0.04 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |